Cargando…

Tracking the CAR-T Revolution: Analysis of Clinical Trials of CAR-T and TCR-T Therapies for the Treatment of Cancer (1997–2020)

Chimeric antigen receptor and T-cell receptor (CAR-T/TCR-T) cellular immunotherapies have shown remarkable success in the treatment of some refractory B-cell malignancies, with potential to provide durable clinical response for other types of cancer. In this paper, we look at all available FDA CAR-T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ivica, Nikola A., Young, Colin M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392279/ https://www.ncbi.nlm.nih.gov/pubmed/34442199 http://dx.doi.org/10.3390/healthcare9081062

Ejemplares similares

Joining Forces for Cancer Treatment: From “TCR versus CAR” to “TCR and CAR”
por: Teppert, Karin, et al.
Publicado: (2022)

TCR-like CARs and TCR-CARs targeting neoepitopes: an emerging potential
por: Poorebrahim, Mansour, et al.
Publicado: (2021)

CAR-T cell combination therapy: the next revolution in cancer treatment
por: Al-Haideri, Maysoon, et al.
Publicado: (2022)

Challenges of CAR- and TCR-T cell–based therapy for chronic infections
por: Bertoletti, Antonio, et al.
Publicado: (2020)

CAR NK-92 cell–mediated depletion of residual TCR(+) cells for ultrapure allogeneic TCR-deleted CAR T-cell products
por: Kath, Jonas, et al.
Publicado: (2023)

The Enigmatic Nature of the TCR-pMHC Interaction: Implications for CAR-T and TCR-T Engineering
por: Shevyrev, D. V., et al.
Publicado: (2022)

A Costimulatory CAR Improves TCR-based Cancer Immunotherapy
por: Omer, Bilal, et al.
Publicado: (2022)

Clinical development of CAR T cell therapy in China: 2020 update
por: Wei, Jianshu, et al.
Publicado: (2020)

Revolution of CAR Engineering For Next-Generation Immunotherapy In Solid Tumors
por: Yu, Tao, et al.
Publicado: (2022)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

Single-Domain Antibody-Based TCR-Like CAR-T: A Potential Cancer Therapy
por: Zhu, Lichen, et al.
Publicado: (2020)

Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells
por: MacLeod, Daniel T., et al.
Publicado: (2017)

Seatbelts in CAR therapy: How Safe Are CARS?
por: Minagawa, Kentaro, et al.
Publicado: (2015)

Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Kulemzin, Sergey, et al.
Publicado: (2021)

Adoptive Cellular Therapy for Multiple Myeloma Using CAR- and TCR-Transgenic T Cells: Response and Resistance
por: Füchsl, Franziska, et al.
Publicado: (2022)

Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany
por: Albinger, Nawid, et al.
Publicado: (2021)

CAR-J cells for antibody discovery and lead optimization of TCR-like immunoglobulins
por: Jost, Christian, et al.
Publicado: (2020)

TCR-Like CAR-T Cells Targeting MHC-Bound Minor Histocompatibility Antigens
por: Akatsuka, Yoshiki
Publicado: (2020)

Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells
por: Hiltensperger, Michael, et al.
Publicado: (2023)

Therapeutic targeting of PRAME with (mTCR)CAR T cells in acute myeloid leukemia
por: Kirkey, Danielle C., et al.
Publicado: (2022)

The development of CAR design for tumor CAR-T cell therapy
por: Xu, Dandan, et al.
Publicado: (2018)

Engineering switchable and programmable universal CARs for CAR T therapy
por: Liu, Delong, et al.
Publicado: (2019)

Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia
por: Zhao, Juanjuan, et al.
Publicado: (2019)

Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy
por: Kilgour, Marisa K., et al.
Publicado: (2023)

CARs and Drugs: Pharmacological Ways of Boosting CAR-T-Cell Therapy
por: Harrer, Dennis Christoph, et al.
Publicado: (2023)

Application of droplet digital PCR for the detection of vector copy number in clinical CAR/TCR T cell products
por: Lu, Alex, et al.
Publicado: (2020)

Clinical trials of CAR-T cells in China
por: Liu, Bingshan, et al.
Publicado: (2017)

Treatment of B cells malignancies with anti-CD19 CAR+, TCR-, CD52- allogeneic T cells
por: Mannioui, Cécile Schiffer, et al.
Publicado: (2013)

Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure
por: Wachsmann, Tassilo L. A., et al.
Publicado: (2022)

CRASH-IT Switch Enables Reversible and Dose-Dependent Control of TCR and CAR T-cell Function
por: Sahillioglu, Ali Can, et al.
Publicado: (2021)

Establishment and validation of in-house cryopreserved CAR/TCR-T cell flow cytometry quality control
por: Cai, Yihua, et al.
Publicado: (2021)

Exploring TCR-like CAR-Engineered Lymphocyte Cytotoxicity against MAGE-A4
por: Alsalloum, Alaa, et al.
Publicado: (2023)

CAR-T Cell Therapy
por: Ahmad, Aamir
Publicado: (2020)

Efficiency of CAR-T Therapy for Treatment of Solid Tumor in Clinical Trials: A Meta-Analysis
por: Hou, Bin, et al.
Publicado: (2019)

Combining BCMA-targeting CAR T cells with TCR-engineered T-cell therapy to prevent immune escape of multiple myeloma
por: Wachsmann, Tassilo L. A., et al.
Publicado: (2023)

Conventional CARs versus modular CARs
por: Feldmann, Anja, et al.
Publicado: (2019)

Allogeneic TCRαβ deficient CAR T-cells targeting CD123 in acute myeloid leukemia
por: Sugita, Mayumi, et al.
Publicado: (2022)

New CAR Designs: Highlights From SOHO 2020
Publicado: (2021)

Filgrastim associations with CAR T‐cell therapy
por: Gaut, Daria, et al.
Publicado: (2020)

Current updates on generations, approvals, and clinical trials of CAR T-cell therapy
por: Asmamaw Dejenie, Tadesse, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v8f1ujjsgljh74ajobqcc5vfm2